Enlivex Therapeutics (NASDAQ:ENLV) Trading Down 3% – Time to Sell?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV)’s share price dropped 3% during trading on Tuesday . The company traded as low as $0.6810 and last traded at $0.6926. Approximately 355,538 shares were traded during trading, a decline of 12% from the average daily volume of 402,283 shares. The stock had previously closed at $0.7142.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ENLV shares. Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 25th. HC Wainwright boosted their price objective on Enlivex Therapeutics from $13.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $16.50.

Enlivex Therapeutics Stock Up 4.8%

The company has a market cap of $167.35 million, a P/E ratio of -1.28 and a beta of 1.47. The business has a fifty day moving average price of $0.81 and a 200-day moving average price of $0.94.

Institutional Investors Weigh In On Enlivex Therapeutics

Institutional investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of Enlivex Therapeutics during the fourth quarter worth approximately $33,000. Susquehanna International Group LLP bought a new stake in shares of Enlivex Therapeutics in the third quarter valued at approximately $57,000. Invesco Ltd. bought a new stake in shares of Enlivex Therapeutics in the fourth quarter valued at approximately $43,000. XTX Topco Ltd boosted its stake in shares of Enlivex Therapeutics by 44.8% in the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after buying an additional 19,132 shares during the period. Finally, Jane Street Group LLC boosted its stake in shares of Enlivex Therapeutics by 244.1% in the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after buying an additional 52,553 shares during the period. Institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.